Sustained myeloprotection and economic impact of trilaciclib during first-line chemotherapy for extensive-stage small-cell lung cancer: a propensity score-matched real-world cohort study

Background Chemotherapy-induced hematologic toxicity remains a challenge in extensive-stage small-cell lung cancer (ES-SCLC). We evaluated associations between trilaciclib use, hematologic toxicity, cumulative toxicity burden, and supportive care drug-cost offsets. Methods This retrospective study compared first-line platinum–etoposide chemotherapy with or without trilaciclib. Propensity score matching targeted a 1:2 ratio. Matched-set regression, generalized estimating equations, and count and recurrence models assessed patient-level, longitudinal, and cumulative outcomes. Sensitivity analyses assessed residual confounding. Growth factor drug-cost offsets were explored. Results Among 461 screened patients, 135 matched patients (49 trilaciclib, 86 controls) were included. Trilaciclib use was associated with lower grade 3–4 hematologic toxicity (16.3% vs 52.3%; OR, 0.20; P < 0.001), neutropenia (16.3% vs 48.8%; OR, 0.23; P < 0.001), and granulocyte colony-stimulating factor utilization (55.1% vs 82.6%; OR, 0.32; P = 0.003). Cycle-adjusted analyses supported these associations; no significant treatment-by-cycle interactions were detected. Cumulative toxicity burden was lower with trilaciclib (median affected cycles per patient, 0 vs 1; P = 0.003), with fewer recurrent grade 3–4 toxicity events (4.1% vs 20.9%; P = 0.029). Under a four-cycle daily whole-vial costing scenario, estimated trilaciclib costs were RMB 11,184 per patient, with growth factor drug-cost offsets of RMB 380 (95% bootstrap CI, − 147 to 911). Sensitivity analyses yielded directionally consistent estimates. Conclusions Trilaciclib use was associated with lower severe hematologic toxicity, cumulative toxicity burden, and supportive care requirements. Estimated growth factor drug-cost offsets covered only a small proportion of acquisition costs. Comprehensive economic evaluations incorporating broader clinical benefits are warranted.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11615447/v1
Primary Topic
Lung Cancer Research Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Sustained myeloprotection and economic impact of trilaciclib during first-line chemotherapy for extensive-stage small-cell lung cancer: a propensity score-matched real-world cohort study

Tingxiu Xiang, Wen Chen, Yubingxue Liu, Li Li
5 links
Research Square
Lung Cancer Research Studies
preprint

Sustained myeloprotection and economic impact of trilaciclib during first-line chemotherapy for extensive-stage small-cell lung cancer: a propensity score-matched real-world cohort study

Tingxiu Xiang, Wen Chen, Yubingxue Liu, Li Li
preprint en

Abstract

Background Chemotherapy-induced hematologic toxicity remains a challenge in extensive-stage small-cell lung cancer (ES-SCLC). We evaluated associations between trilaciclib use, hematologic toxicity, cumulative toxicity burden, and supportive care drug-cost offsets. Methods This retrospective study compared first-line platinum–etoposide chemotherapy with or without trilaciclib. Propensity score matching targeted a 1:2 ratio. Matched-set regression, generalized estimating equations, and count and recurrence models assessed patient-level, longitudinal, and cumulative outcomes. Sensitivity analyses assessed residual confounding. Growth factor drug-cost offsets were explored. Results Among 461 screened patients, 135 matched patients (49 trilaciclib, 86 controls) were included. Trilaciclib use was associated with lower grade 3–4 hematologic toxicity (16.3% vs 52.3%; OR, 0.20; P < 0.001), neutropenia (16.3% vs 48.8%; OR, 0.23; P < 0.001), and granulocyte colony-stimulating factor utilization (55.1% vs 82.6%; OR, 0.32; P = 0.003). Cycle-adjusted analyses supported these associations; no significant treatment-by-cycle interactions were detected. Cumulative toxicity burden was lower with trilaciclib (median affected cycles per patient, 0 vs 1; P = 0.003), with fewer recurrent grade 3–4 toxicity events (4.1% vs 20.9%; P = 0.029). Under a four-cycle daily whole-vial costing scenario, estimated trilaciclib costs were RMB 11,184 per patient, with growth factor drug-cost offsets of RMB 380 (95% bootstrap CI, − 147 to 911). Sensitivity analyses yielded directionally consistent estimates. Conclusions Trilaciclib use was associated with lower severe hematologic toxicity, cumulative toxicity burden, and supportive care requirements. Estimated growth factor drug-cost offsets covered only a small proportion of acquisition costs. Comprehensive economic evaluations incorporating broader clinical benefits are warranted.

Research Square
Chongqing University (CN), Hebei Yiling Hospital (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Chongqing Cancer Hospital (CN)
Good health and well-being
Lung Cancer Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon